Cogent Biosciences (COGT) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 9, 2026, with voting on director elections, auditor ratification, and executive compensation approval.

• The company reported transformative clinical trial results for bezuclastinib, leading to significant increases in market capitalization and regulatory progress.

• The company is preparing for its first commercial launch in the second half of 2026 and has strengthened its balance sheet with major public offerings.

• Forward-looking statements highlight anticipated regulatory submissions, commercial launches, and continued pipeline development.

Voting matters and shareholder proposals

• Stockholders will vote on electing three Class II directors, ratifying PricewaterhouseCoopers LLP as auditor, and approving executive compensation on an advisory basis.

• The board recommends voting for all director nominees and for both auditor ratification and executive compensation proposals.

• No other matters are currently anticipated for the meeting, but proxies may vote on additional matters if they arise.

Board of directors and corporate governance

• The board consists of seven members divided into three classes, with staggered three-year terms.

• The board is majority independent, with only the CEO classified as non-independent.

• Committees include Audit, Compensation, Nominating, and Science, all composed of independent directors.

• The company maintains a classified board, supermajority voting for certain actions, and does not allow stockholders to call special meetings or act by written consent.

• Board diversity is considered, with representation of women and LGBTQ+ members.